Otamixaban

{{Drugbox | Verifiedfields = changed | verifiedrevid = 462266309 | IUPAC_name = Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate | image = Otamixaban.png | image2 = Otamixaban 3D.png

| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ^N | CAS_number = 193153-04-7 | ATC_prefix = none | ATC_suffix = | PubChem = 5496659 | DrugBank_Ref =  ^Y | DrugBank = | ChemSpiderID_Ref =  ^Y | ChemSpiderID = 4593439 | UNII_Ref =  ^Y | UNII = S173RED00L | ChEMBL_Ref =  ^Y | ChEMBL = 46618

| C=25 | H=26 | N=4 | O=4 | molecular_weight = 446.498 g/mol | smiles = O=C(OC)[C@H](Cc1cc(C(=[N@H])N)ccc1)[C@H](NC(=O)c3ccc(c2cc[n+]([O-])cc2)cc3)C | InChI = 1/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1 | InChIKey = PFGVNLZDWRZPJW-OPAMFIHVBD | StdInChI_Ref =  ^Y | StdInChI = 1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1 | StdInChIKey_Ref =  ^Y | StdInChIKey = PFGVNLZDWRZPJW-OPAMFIHVSA-N }}

WikiDoc Resources for Otamixaban
Articles
Most recent articles on Otamixaban Most cited articles on Otamixaban Review articles on Otamixaban Articles on Otamixaban in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Otamixaban Images of Otamixaban Photos of Otamixaban Podcasts & MP3s on Otamixaban Videos on Otamixaban
Evidence Based Medicine
Cochrane Collaboration on Otamixaban Bandolier on Otamixaban TRIP on Otamixaban
Clinical Trials
Ongoing Trials on Otamixaban at Clinical Trials.gov Trial results on Otamixaban Clinical Trials on Otamixaban at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Otamixaban NICE Guidance on Otamixaban NHS PRODIGY Guidance FDA on Otamixaban CDC on Otamixaban
Books
Books on Otamixaban
News
Otamixaban in the news Be alerted to news on Otamixaban News trends on Otamixaban
Commentary
Blogs on Otamixaban
Definitions
Definitions of Otamixaban
Patient Resources / Community
Patient resources on Otamixaban Discussion groups on Otamixaban Patient Handouts on Otamixaban Directions to Hospitals Treating Otamixaban Risk calculators and risk factors for Otamixaban
Healthcare Provider Resources
Symptoms of Otamixaban Causes & Risk Factors for Otamixaban Diagnostic studies for Otamixaban Treatment of Otamixaban
Continuing Medical Education (CME)
CME Programs on Otamixaban
International
Otamixaban en Espanol Otamixaban en Francais
Business
Otamixaban in the Marketplace Patents on Otamixaban
Experimental / Informatics
List of terms related to Otamixaban

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor, that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.